William Blair Analysts Highlight Carterra as AI Drug Discovery Leader

Report cites Carterra's role in enabling AI-powered life science tools for drug development.

Apr. 8, 2026 at 5:45pm

Got story updates? Submit your updates here. ›

A bold, abstract painting in earthy tones of green, brown, and blue, featuring sweeping geometric arcs, concentric circles, and precise botanical spirals, conceptually representing the complex scientific forces and processes involved in AI-powered drug discovery.As AI becomes more integrated into drug discovery workflows, life science tools that enable wet lab experimentation and validation are seen as crucial enablers of this transformative technology.Salt Lake City Today

William Blair analysts Matthew Larew and Jacob Krahenbuhl published a report highlighting Carterra, a life science tools company, as a key player in enabling AI-powered drug discovery workflows. The analysts assert that wet lab experiments will likely increase as AI becomes more integrated into drug development processes, and they identified Carterra as a 'Winner' in this space.

Why it matters

The increasing use of AI in drug discovery has significant implications for the life science tools industry, as wet lab experiments remain crucial even as computational methods advance. Carterra's technology, which supports high-throughput protein interaction analysis, is seen as an important enabler of AI-driven drug development.

The details

In their white paper 'From Code to Clinic: How AI Is (and Isn't) Transforming Drug Discovery,' the William Blair analysts highlighted Carterra's role in providing life science tools that complement AI-powered workflows. The analysts believe that as AI becomes more integrated into drug discovery, the need for wet lab validation and experimentation will grow, benefiting companies like Carterra that offer technologies to support these processes.

  • The William Blair report was published on April 8, 2026.

The players

William Blair

A global investment banking and asset management firm.

Matthew Larew

A William Blair analyst who co-authored the report on AI in drug discovery.

Jacob Krahenbuhl

A William Blair analyst who co-authored the report on AI in drug discovery.

Carterra

A life science tools company that provides technology to support high-throughput protein interaction analysis, which is seen as an important enabler of AI-driven drug development.

Got photos? Submit your photos here. ›

The takeaway

This report highlights the growing importance of life science tools companies like Carterra in supporting the integration of AI into drug discovery workflows. As computational methods advance, the need for wet lab validation and experimentation remains crucial, creating opportunities for technology providers that can enable these complementary processes.